The invention relates to radioimmunoconjugates for the in-vivo elimination of virus-replicating cells in patients infected with the hepatitis C virus (HCV). The inventive radioimmunoconjugates are characterized in that they contain, as immunologically active components, (a) a monoclonal antibody or the antigen-binding fragment thereof directed against a viral or virus-induced antigen expressed on the plasma membrane of HCV-infected cells; (b) a receptor molecule or a fragment of the receptor molecule with an affinity to an epitope of the surface glycoproteins E1 and/or E2, or; C) a fragment of the receptor molecule, said fragment being modified by random or selective mutagenesis, with an affinity to an epitope of the surface glycoproteins E1 and/or E2. In addition, the radioimmunoconjugates are characterized in that they contain, as radioactive components, a radioisotope having a shorter half-life and a lower range, for example, d) J, or e) P, or f) Y, or g) Sr. The radioimmunoconjugates are contained together with pharmaceutical supporting materials and/or auxiliary agents.